Home › Compare › CHMMF vs MRK

CHMMF vs MRK: Dividend Comparison 2026

CHMMF yields 200000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHMMF wins by $4.911780474428384e+29M in total portfolio value
10 years
CHMMF
CHMMF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full CHMMF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CHMMF vs MRK

📍 CHMMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHMMFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHMMF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CHMMF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHMMF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CHMMF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHMMF + MRK for your $10,000?

CHMMF: 50%MRK: 50%
100% MRK50/50100% CHMMF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CHMMF
No analyst data
Altman Z
-32.8
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHMMF buys
0
MRK buys
0
No recent congressional trades found for CHMMF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHMMFMRK
Forward yield200000.00% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$4.911780474428384e+29M$56.8K ✓
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00 ✓$9,798.13
Total dividends collected$4.911464459982279e+29M$28.9K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHMMF vs MRK ($10,000, DRIP)

YearCHMMF PortfolioCHMMF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$20,010,700$20,000,000.00$11,206$366.19+$20.00M → CHMMF
2$37,424,589,019$37,403,177,570.09$12,650$502.35+$37424.58M → CHMMF
3$65,416,215,188,220$65,376,170,877,969.18$14,407$694.19+$65416215.17M → CHMMF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$16,585$967.82+$106868230494.99M → CHMMF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$19,342$1,363.89+$163172871735896.84M → CHMMF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$22,913$1,947.19+$232854599801468864.00M → CHMMF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$27,662$2,823.89+$310570858137017057280.00M → CHMMF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$34,159$4,173.35+$3.871481543016132e+23M → CHMMF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$43,337$6,308.80+$4.510617497632811e+26M → CHMMF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$56,776$9,798.13+$4.911780474428384e+29M → CHMMF

CHMMF vs MRK: Complete Analysis 2026

CHMMF — Stock

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Full CHMMF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CHMMF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHMMF vs SCHDCHMMF vs JEPICHMMF vs OCHMMF vs KOCHMMF vs MAINCHMMF vs JNJCHMMF vs ABBVCHMMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.